BRPI1014390A2 - composto de sal de amônio quaternário, composição medicinal, e, agente preventivo ou terapêutico - Google Patents
composto de sal de amônio quaternário, composição medicinal, e, agente preventivo ou terapêuticoInfo
- Publication number
- BRPI1014390A2 BRPI1014390A2 BRPI1014390A BRPI1014390A BRPI1014390A2 BR PI1014390 A2 BRPI1014390 A2 BR PI1014390A2 BR PI1014390 A BRPI1014390 A BR PI1014390A BR PI1014390 A BRPI1014390 A BR PI1014390A BR PI1014390 A2 BRPI1014390 A2 BR PI1014390A2
- Authority
- BR
- Brazil
- Prior art keywords
- preventative
- therapeutic agent
- quaternary ammonium
- ammonium salt
- salt compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009110760 | 2009-04-30 | ||
| PCT/JP2010/057422 WO2010126025A1 (ja) | 2009-04-30 | 2010-04-27 | 四級アンモニウム塩化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1014390A2 true BRPI1014390A2 (pt) | 2016-04-05 |
Family
ID=43032170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1014390A BRPI1014390A2 (pt) | 2009-04-30 | 2010-04-27 | composto de sal de amônio quaternário, composição medicinal, e, agente preventivo ou terapêutico |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9072734B2 (pt) |
| EP (1) | EP2426121A4 (pt) |
| JP (1) | JP5379224B2 (pt) |
| KR (1) | KR20120061061A (pt) |
| CN (1) | CN102459231B (pt) |
| AR (1) | AR078121A1 (pt) |
| AU (1) | AU2010242646A1 (pt) |
| BR (1) | BRPI1014390A2 (pt) |
| CA (1) | CA2760630A1 (pt) |
| IL (1) | IL216015A0 (pt) |
| MX (1) | MX2011011446A (pt) |
| MY (1) | MY155212A (pt) |
| NZ (1) | NZ595810A (pt) |
| SG (1) | SG177468A1 (pt) |
| TW (1) | TWI486343B (pt) |
| WO (1) | WO2010126025A1 (pt) |
| ZA (1) | ZA201108372B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| ME02297B (me) * | 2011-06-10 | 2016-02-20 | Chiesi Farm Spa | Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| BR112015012730B1 (pt) * | 2012-12-06 | 2022-07-05 | Chiesi Farmaceutici S.P.A. | Composto, composição farmaceutica, dispositivo, uso de um composto e combinação |
| MA38260B1 (fr) | 2012-12-18 | 2018-04-30 | Almirall Sa | Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| KR20160148589A (ko) * | 2014-04-25 | 2016-12-26 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 루테늄 촉매반응에 의한 아닐리드로부터 비페닐아민의 제조방법 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| CN104557589A (zh) * | 2014-12-24 | 2015-04-29 | 天津大学 | N-(1，1’-二芳基)取代的酰胺类衍生物的制备方法 |
| CN107108502A (zh) * | 2015-05-14 | 2017-08-29 | 四川海思科制药有限公司 | 具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途 |
| CN107108562B (zh) * | 2015-05-14 | 2020-07-10 | 四川海思科制药有限公司 | 具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途 |
| RU2722720C1 (ru) * | 2016-12-14 | 2020-06-03 | Бейджинг Шоубай Фармасьютикэл Ко., Лтд. | Класс бифункциональных соединений со структурой соли четвертичного аммония |
| CN108854841B (zh) * | 2018-06-25 | 2020-09-29 | 长治学院 | 一种连接基含酯基的吡咯烷类手性Gemini表面活性剂及其制备方法 |
| US11841822B2 (en) | 2019-04-27 | 2023-12-12 | Cambricon Technologies Corporation Limited | Fractal calculating device and method, integrated circuit and board card |
| WO2020220935A1 (zh) | 2019-04-27 | 2020-11-05 | 中科寒武纪科技股份有限公司 | 运算装置 |
| CN111217746B (zh) * | 2020-03-10 | 2021-09-24 | 佛山市隆信医药科技有限公司 | 一种盐酸丙卡特罗的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3240784A (en) * | 1966-03-15 | Esters of quaternary z-hydroxy methyl piperidinium compounds | ||
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| WO2004007426A1 (en) | 2002-07-17 | 2004-01-22 | Chiang Long Y | Fullerene compounds |
| CN101239971B (zh) * | 2003-02-14 | 2011-07-20 | 施万制药 | 联苯衍生物 |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| JP4767842B2 (ja) | 2003-04-01 | 2011-09-07 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物 |
| CA2638788A1 (en) | 2003-04-25 | 2004-11-11 | Kos Life Sciences, Inc. | Formation of strong superporous hydrogels |
| DE602004021921D1 (de) | 2003-05-28 | 2009-08-20 | Theravance Inc | Azabicycloalkanverbindungen als muscarinrezeptor antagonisten |
| EP1656370B1 (en) * | 2003-06-03 | 2012-08-15 | Rib-X Pharmaceuticals, Inc. | Biaryl heterocyclic compounds and methods of making and using the same |
| PE20050231A1 (es) * | 2003-06-24 | 2005-05-20 | Novartis Ag | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 |
| TW200534855A (en) | 2004-01-13 | 2005-11-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| WO2007107828A2 (en) | 2006-03-20 | 2007-09-27 | Pfizer Limited | Amine derivatives |
| GB0702413D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New chemical compounds |
| PL2242759T3 (pl) | 2008-02-06 | 2013-06-28 | Astrazeneca Ab | Związki |
-
2010
- 2010-04-27 MX MX2011011446A patent/MX2011011446A/es active IP Right Grant
- 2010-04-27 WO PCT/JP2010/057422 patent/WO2010126025A1/ja not_active Ceased
- 2010-04-27 BR BRPI1014390A patent/BRPI1014390A2/pt not_active IP Right Cessation
- 2010-04-27 CN CN201080029330.3A patent/CN102459231B/zh not_active Expired - Fee Related
- 2010-04-27 JP JP2011511402A patent/JP5379224B2/ja not_active Expired - Fee Related
- 2010-04-27 NZ NZ595810A patent/NZ595810A/xx not_active IP Right Cessation
- 2010-04-27 MY MYPI2011005166A patent/MY155212A/en unknown
- 2010-04-27 US US13/266,651 patent/US9072734B2/en not_active Expired - Fee Related
- 2010-04-27 EP EP10769723A patent/EP2426121A4/en not_active Withdrawn
- 2010-04-27 KR KR1020117028059A patent/KR20120061061A/ko not_active Withdrawn
- 2010-04-27 SG SG2011097920A patent/SG177468A1/en unknown
- 2010-04-27 CA CA2760630A patent/CA2760630A1/en active Pending
- 2010-04-27 AU AU2010242646A patent/AU2010242646A1/en not_active Abandoned
- 2010-04-29 AR ARP100101446A patent/AR078121A1/es unknown
- 2010-04-30 TW TW099113895A patent/TWI486343B/zh not_active IP Right Cessation
-
2011
- 2011-10-27 IL IL216015A patent/IL216015A0/en unknown
- 2011-11-15 ZA ZA2011/08372A patent/ZA201108372B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY155212A (en) | 2015-09-30 |
| CN102459231A (zh) | 2012-05-16 |
| TWI486343B (zh) | 2015-06-01 |
| US20120046467A1 (en) | 2012-02-23 |
| IL216015A0 (en) | 2012-01-31 |
| AR078121A1 (es) | 2011-10-19 |
| WO2010126025A1 (ja) | 2010-11-04 |
| JP5379224B2 (ja) | 2013-12-25 |
| TW201103909A (en) | 2011-02-01 |
| ZA201108372B (en) | 2012-07-25 |
| EP2426121A1 (en) | 2012-03-07 |
| CA2760630A1 (en) | 2010-11-04 |
| KR20120061061A (ko) | 2012-06-12 |
| AU2010242646A1 (en) | 2011-11-03 |
| JPWO2010126025A1 (ja) | 2012-11-01 |
| NZ595810A (en) | 2013-05-31 |
| SG177468A1 (en) | 2012-02-28 |
| US9072734B2 (en) | 2015-07-07 |
| HK1166790A1 (en) | 2012-11-09 |
| CN102459231B (zh) | 2015-04-22 |
| MX2011011446A (es) | 2011-11-18 |
| EP2426121A4 (en) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1014390A2 (pt) | composto de sal de amônio quaternário, composição medicinal, e, agente preventivo ou terapêutico | |
| BR112013013311A2 (pt) | agente terapêutico de indução de citotoxicidade | |
| BR112013011968A2 (pt) | composição farmacêutica, métodos de tratamento e usos da mesma | |
| BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
| BRPI0819361A2 (pt) | Composição de tratamento de cabelos e agente de tratamento | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BRPI0919519A2 (pt) | Composição, agente herbicida, e, usos de herbicida, e da composição | |
| PT2435025T (pt) | Administração, por via respiratória, de agentes activos | |
| BR112014009634A2 (pt) | preparação e agente terapêutico | |
| BRPI0908021A2 (pt) | Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica | |
| BRPI0806531A2 (pt) | Composto, composição farmacêutica, agente terapêutico, e, uso do composto. | |
| IL193746A (en) | Antimicrobial compositions and catheters containing the same and methods for production thereof | |
| BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| EP3068442A4 (en) | Bionanofluid for use as a contrast, imaging, disinfecting and/or therapeutic agent | |
| PT2729151T (pt) | Composição farmacêutica, métodos de tratamento e suas utilizações | |
| BRPI1009372A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| PL2338519T3 (pl) | Środek do leczenia zwłóknienia szpiku | |
| BRPI0809656A2 (pt) | Atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica | |
| BRPI1009860A2 (pt) | composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais | |
| BRPI1013763A2 (pt) | Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto | |
| DK2108260T3 (da) | Sammensætning med biocid aktivitet til vandige præparater | |
| BRPI0821720A2 (pt) | Aplicação de líquidos iônicos, magnéticos como agente de extração | |
| BR112014025299A8 (pt) | anticorpo de reação cruzada dirigido contra staphylococcus aureus, preparação farmacêutica e diagnóstica compreendendo o anticorpo, métodos de anticorpo de reação cruzada contra staphylococcus aureus | |
| CL2014003148A1 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición. | |
| ZA201203281B (en) | Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |